Aducanumab’s mechanism of action

Aducanumab (Aducanumab) is a monoclonal IgG1 antibody that binds to amyloid beta at amino acids 3-7.1. The amyloid beta residues Phe4, His6, Glu3, and Arg5 are responsible for most of the contacts between amyloid beta and the aducanumab Fab region. Data from studies in mice and humans show that aducanumab treatment reduces amyloid beta, whereas human trials show no significant changes in amyloid beta40 and amyloid beta42 and an increase in amyloid beta42 over the dose range of 0.3-30 mg/kg. Treatment with aducanumab was associated with slower progression of Alzheimer's disease, based on the Mini-Mental State Examination, clinical dementia grade, and cerebrospinal fluid p-tau protein levels.